) % Revenue from sales and service 1,788.5 2,025.3 1,187.1 (236.8) (11.7) 601.4 50.7 Cost of sales and service 1,499.5 1,686.8 998.7 (187.3) (11.1) 500.8 50.1 Selling and distribution expenses 73.7 78.7 52.0
sales staffs, advertising media fee for product promotion, distribution fee paid to Zuellig Pharma Ltd. under the Distribution Agreement and compensation for distribution of company’ s products in the
0.00 12.21 N/A 6.95% 0.00% Revenues from reduction of defaulted interest under the Court’s order 16.66 0.00 16.66 N/A 9.48% 0.00% Distribution costs (24.14 ) (26.13 ) (1.99 ) 7.62% (13.74%) (8.83
to gather the names of shareholders under Section 225 of the Securities and Exchange Act B.E. 2535 (as amended) by closing the share register book and suspension of share transfer, as well as to amend
trustee, under Clause 20; (13) the trust’s disclosure of information, under Clause 21; (14) the distribution to the unit holders, under Clause 22; (15) the proposal for resolution and the general meeting of
Asia), as well as stints at Bear, Stearns & Co and Peregrine Capital (USA) Inc. in New York. Mr.Surachet previously served as CEO of Maybank Investment Bank (formerly known as Aseambankers, the
. Mr.Surachet previously served as CEO of Maybank Investment Bank (formerly known as Aseambankers, the investment banking arm of Maybank), as well as Head of Corporate Investment Banking overseeing a portfolio of
structural change in the business outlook of PET, and is an oppor- tunity for well-managed and committed PET producers like IVL to align supply reliability to customers. We benefitted from the instability